Exciting New Development: Durect Corporation Unveils Game-Changing Phase 2b Results for Larsucosterol in The New England Journal of Medicine!
Exciting New Developments in Pharmaceutical Research: A Deep Dive into DURECT Corporation’s AHFIRM Trial CUPERTINO, Calif., Jan. 28, 2025 – In the ever-evolving world of pharmaceutical research, each new discovery brings us one step closer to improving and saving lives. Today, we’re thrilled to share with you the latest advancements from DURECT Corporation (Nasdaq: DRRX)…